We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie has already inked several patent settlements with biosimilar developers looking to take on its megablockbuster Humira, and now the company is back at the deal table with a fourth.